Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non–Small-Cel...

od Langer, Corey J., Novello, Silvia, Park, Keunchil, Krzakowski, Maciej, Karp, Daniel D., Mok, Tony, Benner, Rebecca J., Scranton, Judith R., Olszanski, Anthony J., Jassem, Jacek
Izdano 2014

Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer

od Belani, Chandra P, Nemunaitis, John J, Chachoua, Abraham, Eisenberg, Peter D, Raez, Luiz E, Cuevas, J Daniel, Mather, Cecile B, Benner, Rebecca J, Meech, Sandra J
Izdano 2013

Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia

od Pautas, Cécile, Raffoux, Emmanuel, Lambert, Juliette, Legrand, Ollivier, Chantepie, Sylvain, Gastaud, Lauris, Marolleau, Jean-Pierre, Thomas, Xavier, Turlure, Pascal, Benner, Rebecca J., Vandendries, Erik, Gogat, Karïn, Dombret, Hervé, Castaigne, Sylvie
izdano v Bone Marrow Transplant (2021)

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

od Lambert, Juliette, Pautas, Cécile, Terré, Christine, Raffoux, Emmanuel, Turlure, Pascal, Caillot, Denis, Legrand, Ollivier, Thomas, Xavier, Gardin, Claude, Gogat-Marchant, Karïn, Rubin, Stephen D., Benner, Rebecca J., Bousset, Pierre, Preudhomme, Claude, Chevret, Sylvie, Dombret, Herve, Castaigne, Sylvie
izdano v Haematologica (2019)